Atención médica

Noticias de la sede central en Tokio

Ver todos

• Jun 29, 2022

  Fujifilm to Invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing services

• Abr 4, 2022

  Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.

• Mar 22, 2022

  Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business
  Amendment in relation to a return of domestic marketing rights for a product

• Sep 2, 2021

  Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business to PeptiDream

• Ago 31, 2021

  Launch of Therapeutic Radiopharmaceutical Product, Lutathera^® Injection targeting neuroendocrine tumors in Japan  (FUJIFILM Toyama Chemical)